Skip to Content

Bonefos Approval Status

  • FDA approved: No
  • Brand name: Bonefos
  • Generic name: clodronate
  • Company: Berlex, Inc.
  • Treatment for: Breast Cancer, Adjuvant

Bonefos (clodronate) is a non-amino bisphosphonate intended to reduce the occurrence of bone metastases in the post-surgical (adjuvant) treatment of breast cancer patients.

In January 2005, Berlex, Inc. announced the receipt of an Approvable Letter from the U.S. Food and Drug Administration (FDA), advising the company that approval was dependent upon the results of the ongoing National Surgical Adjuvant Breast and Bowel Project (NSABP) B-34 study. While oral Bonefos is approved in 67 countries outside the United States largely for the treatment of tumor-induced osteolysis and hypercalcemia, it remains commerically undeveloped in the United States.

Development Status and FDA Approval Process for Bonefos

May 11, 2005Further Trial Data Awaited for Bonefos in the U.S.
Jan  7, 2005Berlex Receives Approvable Letter for Bonefos (Clodronate) for Adjuvant Treatment of Breast Cancer
Sep  9, 2004Bonefos Accepted for Filing and Granted Priority Review by FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.